asset acquisition

Amarantus has reacquired LymPro Test, MSPrecise, and NuroPro and said that it plans to assign the assets to a new subsidiary.

Interleukin said in July that it would liquidate its assets after laying off 63 percent of its workforce and suspending sales of its controversial genetic test.

Investment banks Canaccord Genuity and Raymond James also raised their price targets on the company.

Population Genetics was formed to commercialize the IP portfolio of Sydney Brenner focused on high sensitivity and high specificity NGS detection.

The purchase provides Thermo Fisher with access to the $40 billion pharmaceutical contract development and manufacturing market.

The clinical genetics and genomics testing firm said the funding will help as it seeks to consolidate its presence in international markets.

The acquisition of GeneWorks' oligo business widens IDT's reach in the Asia-Pacific region, the company said.